Summary
Abbott Laboratories reported net sales of $5.24 billion for the first quarter of 2014, a decrease of 2.5% year-over-year. This decline was primarily driven by unfavorable foreign exchange rates, which reduced international sales by 4.1%. Excluding the impact of foreign exchange, total net sales saw a slight increase of 0.5%, boosted by strong performance in Diagnostic Products, particularly in core laboratory diagnostics and international molecular sales. However, Nutritional Products experienced a 4.0% sales decrease, largely attributed to a supplier recall in August 2013 impacting pediatric products in certain international markets. The company also announced a significant increase in its quarterly dividend to $0.22 per share, up 57% from the previous year, signaling confidence in its financial position and future prospects. Share repurchases also continued actively, with $2.19 billion spent in the quarter under a new $3 billion authorization. Despite the top-line challenges, Abbott is focused on cost management and strategic initiatives, including planned restructuring actions across its vascular, diagnostics, and nutritional businesses to improve efficiency.
Financial Highlights
52 data points| Revenue | $4.75B |
| Cost of Revenue | $2.27B |
| Gross Profit | $2.35B |
| SG&A Expenses | $1.62B |
| Operating Expenses | $4.39B |
| Operating Income | $365.00M |
| Interest Expense | $36.00M |
| Net Income | $375.00M |
| EPS (Basic) | $0.24 |
| EPS (Diluted) | $0.24 |
| Shares Outstanding (Basic) | 1.53B |
| Shares Outstanding (Diluted) | 1.55B |
Key Highlights
- 1Net sales decreased 2.5% to $5.24 billion, largely due to unfavorable foreign exchange, though underlying sales excluding FX increased 0.5%.
- 2Diagnostic Products showed strong growth (2.6% reported, 5.1% excluding FX), driven by core laboratory diagnostics and international molecular sales.
- 3Nutritional Products sales declined 4.0%, impacted by a prior supplier recall affecting pediatric products in international markets.
- 4Established Pharmaceutical Products sales decreased 6.6% (0.7% excluding FX), affected by currency impacts and planned plant shutdowns for capacity expansion.
- 5The company significantly increased its quarterly dividend by 57% to $0.22 per share.
- 6Abbott repurchased $2.19 billion of its common stock in the quarter, continuing its capital return program.
- 7Restructuring charges of approximately $80 million were recorded for streamlining operations in vascular, diagnostics, and nutritional businesses.